Updates
This is to inform you that the Statutory Auditors B S R & Co. LLP would be completing their maximum term permitted under Section 139 of the Companies Act, 2013 and the Rules made thereunder at the ensuing Annual General Meeting of the Company. In view of the same, the Board of Directors of the Company at their meeting held on May 6, 2017, have recommended, the appointment of Walker Chandiok & Co LLP, Chartered Accountants (Firm... Board recommends Dividend
Pfizer Ltd has informed BSE that the Board of Directors of the Company at its meeting held on May 06, 2017, inter alia, has recommended a normal divided of 150% ( Rs. 15 per equity share of Rs. 10 each) and a special dividend of 50% (Rs. 5 per equity share of Rs. 10 each) on account of exceptional income during the year, aggregating to total dividend of 200% ( Rs. 20 per equity share of Rs. 10 each) for the financial year ended March 31, 2017. The... Pfizer Limited Audited Financial Results For Quarter And Financial Year Ended March 31, 2017
Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we submit herewith audited financial results for the quarter and financial year ended March 31, 2017, which were approved by the Board of Directors of the Company at its Meeting held today, that commenced at 3.30 p.m. and concluded at 5.30 p.m. Further, please be informed that The Board of Directors of the Company has recommended a normal... Board Meeting For The Audited Financial Results For The Quarter And Financial Year Ended March 31, 2017 As On May 6, 2017 And Intimation Of Closure Of Trading Window
Board Meeting for the Audited Financial Results for the quarter and financial year ended March 31, 2017 as on May 6, 2017 and intimation of Closure of Trading Window CERTIFICATE UNDER REGULATION 40 (9) OF SECURITIES AND EXCHANGE BOARD OF INDIA (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015 FOR THE HALF YEAR ENDED 31ST MARCH, 2017 - PFIZER LIMITED
CERTIFICATE UNDER REGULATION 40 (9) OF SECURITIES AND EXCHANGE BOARD OF INDIA (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015 FOR THE HALF YEAR ENDED 31ST MARCH, 2017 - PFIZER LIMITED Shareholding for the Period Ended March 31, 2017
Pfizer Ltd has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2017. For more details, kindly Click here Statement Of Investor Complaints For The Quarter Ended March 31, 2017
Statement for the quarter ended March 31, 2017, under Regulation 13 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 1.Investor complaints pending at the beginning of the quarter - NIL 2.Investor complaints received during the quarter - 17 3.Investor complaints disposed of during the quarter - 17 4.Investor complaints remained unresolved at the end of the quarter - NIL... Compliance Certificate For The Half Year Ended March 31, 2017.
CERTIFICATE UNDER REGULATION 7(3) OF THE SEBI (LISTING OBLIGATIONS & DISCLOSURE REQUIREMENTS) REGULATIONS, 2015 FOR THE HALF YEAR ENDED ON 31st MARCH, 2017 We hereby certify that all the activities in relation to both physical and electronic share transfer facility are maintained by M/s. Karvy Computershare Private Limited, Registrar & Share Transfer Agent holding requisite certificate as Category I Registrar & Share Transfer Agent vide SEBI Registration... Clarifies on News item
With reference to news flashed on CNBC TV18 dated March 24, 2017 quoting "Pfizer's Hospira Vizag Unit Receives 11 observation from US FDA.", Pfizer Ltd has submitted to BSE a copy of Clarification is enclosed. Clarification sought from Pfizer Ltd
The Exchange has sought clarification from Pfizer Ltd on March 24, 2017, with reference to news flashed on CNBC TV18 dated March 24, 2017 quoting "Pfizer's Hospira Vizag Unit Receives 11 observation from US FDA."The reply is awaited.